Literature DB >> 32029588

Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.

Su Yang1, Huiming Yang2,3, Luoxiu Huang4, Luxiao Chen5, Zhaohui Qin5, Shihua Li6, Xiao-Jiang Li1.   

Abstract

Identification of repeat-associated non-AUG (RAN) translation in trinucleotide (CAG) repeat diseases has led to the emerging concept that CAG repeat diseases are caused by nonpolyglutamine products. Nonetheless, the in vivo contribution of RAN translation to the pathogenesis of CAG repeat diseases remains elusive. Via CRISPR/Cas9-mediated genome editing, we established knock-in mouse models that harbor expanded CAG repeats in the mouse huntingtin gene to express RAN-translated products with or without polyglutamine peptides. We found that RAN translation is not detected in the knock-in mouse models when expanded CAG repeats are expressed at the endogenous level. Consistently, the expanded CAG repeats that cannot be translated into polyglutamine repeats do not yield the neuropathological and behavioral phenotypes that were found in knock-in mice expressing expanded polyglutamine repeats. Our findings suggest that RAN-translated products do not play a major role in the pathogenesis of CAG repeat diseases and underscore the importance in targeting polyglutamine repeats for therapeutics.

Entities:  

Keywords:  CAG repeat; Huntington’s disease; aggregates; gene targeting; neurodegeneration

Mesh:

Substances:

Year:  2020        PMID: 32029588      PMCID: PMC7049130          DOI: 10.1073/pnas.1919197117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion.

Authors:  Sara Van Mossevelde; Julie van der Zee; Ilse Gijselinck; Kristel Sleegers; Jan De Bleecker; Anne Sieben; Rik Vandenberghe; Tim Van Langenhove; Jonathan Baets; Olivier Deryck; Patrick Santens; Adrian Ivanoiu; Christiana Willems; Veerle Bäumer; Marleen Van den Broeck; Karin Peeters; Maria Mattheijssens; Peter De Jonghe; Patrick Cras; Jean-Jacques Martin; Marc Cruts; Peter P De Deyn; Sebastiaan Engelborghs; Christine Van Broeckhoven
Journal:  JAMA Neurol       Date:  2017-04-01       Impact factor: 18.302

2.  Non-canonical RAN Translation of CGG Repeats Has Canonical Requirements.

Authors:  Diana C Cox; Thomas A Cooper
Journal:  Mol Cell       Date:  2016-04-21       Impact factor: 17.970

Review 3.  CGG repeat in the FMR1 gene: size matters.

Authors:  R Willemsen; J Levenga; B A Oostra
Journal:  Clin Genet       Date:  2011-06-30       Impact factor: 4.438

Review 4.  Molecular mechanisms and potential therapeutical targets in Huntington's disease.

Authors:  Chiara Zuccato; Marta Valenza; Elena Cattaneo
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

5.  Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease.

Authors:  R G Snell; J C MacMillan; J P Cheadle; I Fenton; L P Lazarou; P Davies; M E MacDonald; J F Gusella; P S Harper; D J Shaw
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

6.  RAN Translation in Huntington Disease.

Authors:  Monica Bañez-Coronel; Fatma Ayhan; Alex D Tarabochia; Tao Zu; Barbara A Perez; Solaleh Khoramian Tusi; Olga Pletnikova; David R Borchelt; Christopher A Ross; Russell L Margolis; Anthony T Yachnis; Juan C Troncoso; Laura P W Ranum
Journal:  Neuron       Date:  2015-11-18       Impact factor: 17.173

7.  CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome.

Authors:  Peter K Todd; Seok Yoon Oh; Amy Krans; Fang He; Chantal Sellier; Michelle Frazer; Abigail J Renoux; Kai-chun Chen; K Matthew Scaglione; Venkatesha Basrur; Kojo Elenitoba-Johnson; Jean P Vonsattel; Elan D Louis; Michael A Sutton; J Paul Taylor; Ryan E Mills; Nicholas Charlet-Berguerand; Henry L Paulson
Journal:  Neuron       Date:  2013-04-18       Impact factor: 17.173

Review 8.  Polyglutamine neurodegeneration: protein misfolding revisited.

Authors:  Aislinn J Williams; Henry L Paulson
Journal:  Trends Neurosci       Date:  2008-09-06       Impact factor: 13.837

9.  Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates.

Authors:  Stéphane Palfi; Emmanuel Brouillet; Béchir Jarraya; Jocelyne Bloch; Caroline Jan; Masahiro Shin; Françoise Condé; Xiao-Jiang Li; Patrick Aebischer; Philippe Hantraye; Nicole Déglon
Journal:  Mol Ther       Date:  2007-05-01       Impact factor: 11.454

10.  Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS.

Authors:  Tania F Gendron; Kevin F Bieniek; Yong-Jie Zhang; Karen Jansen-West; Peter E A Ash; Thomas Caulfield; Lillian Daughrity; Judith H Dunmore; Monica Castanedes-Casey; Jeannie Chew; Danielle M Cosio; Marka van Blitterswijk; Wing C Lee; Rosa Rademakers; Kevin B Boylan; Dennis W Dickson; Leonard Petrucelli
Journal:  Acta Neuropathol       Date:  2013-10-16       Impact factor: 17.088

View more
  9 in total

1.  Huntington's disease brain-derived small RNAs recapitulate associated neuropathology in mice.

Authors:  Jordi Creus-Muncunill; Anna Guisado-Corcoll; Veronica Venturi; Lorena Pantano; Georgia Escaramís; Marta García de Herreros; Maria Solaguren-Beascoa; Ana Gámez-Valero; Cristina Navarrete; Mercè Masana; Franc Llorens; Daniela Diaz-Lucena; Esther Pérez-Navarro; Eulàlia Martí
Journal:  Acta Neuropathol       Date:  2021-02-06       Impact factor: 17.088

Review 2.  CRISPR-Based Genome-Editing Tools for Huntington's Disease Research and Therapy.

Authors:  Yiyang Qin; Shihua Li; Xiao-Jiang Li; Su Yang
Journal:  Neurosci Bull       Date:  2022-05-24       Impact factor: 5.203

Review 3.  A Glimpse of Molecular Biomarkers in Huntington's Disease.

Authors:  Silvia Martí-Martínez; Luis M Valor
Journal:  Int J Mol Sci       Date:  2022-05-12       Impact factor: 6.208

Review 4.  Advances in Modeling Polyglutamine Diseases Using Genome Editing Tools.

Authors:  Marianna Karwacka; Marta Olejniczak
Journal:  Cells       Date:  2022-02-02       Impact factor: 6.600

5.  Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease.

Authors:  Jun Wan Shin; Aram Shin; Seri S Park; Jong-Min Lee
Journal:  Mol Ther Methods Clin Dev       Date:  2022-03-04       Impact factor: 6.698

6.  PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington's disease.

Authors:  Jun Wan Shin; Eun Pyo Hong; Seri S Park; Doo Eun Choi; Sophia Zeng; Richard Z Chen; Jong-Min Lee
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-14       Impact factor: 5.849

Review 7.  Emerging Therapies for Huntington's Disease - Focus on N-Terminal Huntingtin and Huntingtin Exon 1.

Authors:  M Leontien van der Bent; Melvin M Evers; Astrid Vallès
Journal:  Biologics       Date:  2022-09-30

Review 8.  Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.

Authors:  Sarah J Tabrizi; Michael D Flower; Christopher A Ross; Edward J Wild
Journal:  Nat Rev Neurol       Date:  2020-08-14       Impact factor: 42.937

Review 9.  Huntingtin and Its Role in Mechanisms of RNA-Mediated Toxicity.

Authors:  Annika Heinz; Deepti Kailash Nabariya; Sybille Krauss
Journal:  Toxins (Basel)       Date:  2021-07-14       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.